HIV Mutation Detail Information

Virus Mutation HIV Mutation R263K


Basic Characteristics of Mutations
Mutation Site R263K
Mutation Site Sentence Major (E138K and R263K) integrase mutations were detected in 0.45% of cases with minor resistance observed in 14.85%, most commonly (13.95%) E157Q.
Mutation Level Amino acid level
Mutation Type Nonsynonymous substitution
Gene/Protein/Region IN
Standardized Encoding Gene gag-pol:155348
Genotype/Subtype HIV-1 B
Viral Reference -
Functional Impact and Mechanisms
Disease HIV Infections    
Immune -
Target Gene -
Clinical and Epidemiological Correlations
Clinical Information Y
Treatment EVG;DTG;BIC;CAB
Location Polish
Literature Information
PMID 39459930
Title Frequency of Major Transmitted Integrase Resistance in Poland Remains Low Despite Change in Subtype Variability
Author Mielczak K,Serwin K,Urbanska A,Aksak-Was B,Karasinska-Cieslak M,Mularska E,Witor A,Jakubowski P,Hlebowicz M,Bociaga-Jasik M,Jablonowska E,Szymczak A,Szetela B,Lojewski W,Parczewski M
Journal Viruses
Journal Info 2024 Oct 11;16(10):1597
Abstract With the widespread use of integrase inhibitors and the expanding use of long-acting cabotegravir in both pre-exposure prophylaxis and antiretroviral treatment, molecular surveillance on the transmission of integrase resistance has regained clinical significance. This study aimed to determine the frequency of INSTI-transmitted drug resistance mutations (DRMs) among treatment-naive individuals in Poland from 2016 to 2023. INSTI resistance was analyzed in 882 antiretroviral treatment-naive individuals using Sanger sequencing. Integrase DRMs were defined based on the Stanford HIV drug resistance database scores. Phylogeny was used to investigate subtyping and clustering. For the analysis of time-trends, logistic regression was used. Major (E138K and R263K) integrase mutations were detected in 0.45% of cases with minor resistance observed in 14.85%, most commonly (13.95%) E157Q. Overall, no major clusters of transmitted drug resistance were identified, and the transmission of E157Q showed a decreasing trend (p < 0.001). While the frequency of sub-subtype A6 increased, it was predominantly found among migrants and associated with L74 mutations. The frequency of major integrase-transmitted DRMs remains low, despite the changes in subtype variability. Surveillance of changing HIV molecular variation patterns is vital from the perspective of the optimal use of integrase inhibitors, especially due to expanding long-acting cabotegravir implementation.
Sequence Data OP301658;OP301660;OP301669;OP301673;OP301683;OP301685;OP301694;OP301696;OP301707-OP301708;OP301718;OP301725;OP301735;OP301743;OP301745-OP301746;OP301755;OP301757-OP301758;OP301766;OP301781;OP301783;OP301793;OP301801-OP301802;OP301811;OP301825;OP301827-OP301840;OP301842-OP301850;OP301852-OP301876;OP301878-OP301879;OP301881-OP301882;OP301884-OP301885;OP301887-OP301888;OP301890-OP301926;OP301928-OP301929;OP301931-OP301942;OP301944-OP301965;OP301967-OP301996;OP301998-OP302014;OP302016-OP302017;OP302019-OP302021;OP302023-OP302039;OP302041-OP302047;OP302049-OP302059;OP302061-OP302065;OP302067-OP302068;OP302070-OP302071;OP302073-OP302080;OP302083-OP302085;OP302087-OP302090;OP302092-OP302095;OP302097;OP302099-OP302104;OP302106-OP302108;OP302110-OP302112;OP302115-OP302118;OP302120-OP302121;OP302123;OP302126-OP302128;OP302131;OP302133-OP302138;OP302140-OP302145;OP302147-OP302154;OP302156-OP302167;OP302170-OP302174;OP302176;OP302178-OP302183;OP302185-OP302187;OP302190;OP302192-OP302199;OP302201;OP302203-OP302205;OP302208-OP302209;OP302211-OP302212;OP302215-OP302219;OP302221-OP302230;OP302232;OP302235-OP302256;OP302258;OP302263-OP302269;OP302272-OP302273;OP302275-OP302278;OP302281-OP302285;OP302287-OP302294;OP302296-OP302304;OP302306;OP302308-OP302310;OP302312-OP302318;OP302320-OP302326;OP302328-OP302334;OP302336-OP302341;OP302343-OP302353;OP302355-OP302360;OP302363-OP302367;OP302369-OP302376;OP302378-OP302382;OP302384-OP302385;OP302387;OP302389;OP302391-OP302395;OP302397-OP302402;OP302404;OP302408-OP302409;OP302411-OP302415;OP302417-OP302418;OP302420-OP302429;OP302431-OP302434;OP302436-OP302437;OP302439-OP302442;OP302444;OP302446-OP302454;OP302456;OP302458-OP302459;OP302462-OP302464;OP302468-OP302470;OP302472-OP302481;OP302483-OP302488;OP302490-OP302492;OP302494;OP302496-OP302498;OP302500-OP302505;OP302507-OP302509;OP302513-OP302519;OP302521-OP302528;OP302530;OP302536-OP302538;OP302540-OP302541;OP302543;OP302546;OP302548;OP302550-OP302551;OP302553-OP302554;OP302556-OP302558;OP302563;OP302566-OP302567;OP302573-OP302576;OP302581-OP302583;OP302586;OP302591;OP302594;OP302596;OP302599-OP302600;OP302605;OP302610;OP302612;OP302616;OP302618-OP302621;OP302623;OP302625;OP302628;OP302630;OP302638-OP302639;OP302642-OP302643;OP302648;OP302651;OP302658;OP302662;OP302670;OP302676;OP302680;OP302683-OP302684;OP302689;OP302696;OP302700;OP302703-OP302705;OP302708;OP302711;OP302713;OP302716;OP302720-OP302722;OP302727.
Mutation Information
Note
Basic Characteristics of Mutations
  • Mutation Site: The specific location in a gene or protein sequence where a change occurs.
  • Mutation Level: The level at which a mutation occurs, including the nucleotide or amino acid level.
  • Mutation Type: The nature of the mutation, such as missense mutation, nonsense mutation, synonymous mutation, etc.
  • Gene/Protein/Region: Refers to the specific region of the virus where the mutation occurs. Including viral genes, viral proteins, or a specific viral genome region. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main
  • Gene/Protein/Region studied in the article is marked.
  • Genotype/Subtype: Refers to the viral genotype or subtype where the mutation occurs. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main Genotype/Subtype studied in the article is marked.
  • Viral Reference: Refers to the standard virus strain used to compare and analyze viral sequences.
Functional Impact and Mechanisms
  • Disease: An abnormal physiological state with specific symptoms and signs caused by viral infection.
  • Immune: The article focuses on the study of mutations and immune.
  • Target Gene: Host genes that viral mutations may affect.
Clinical and Epidemiological Correlations
  • Clinical Information: The study is a clinical or epidemiological study and provides basic information about the population.
  • Treatment: The study mentioned a certain treatment method, such as drug resistance caused by mutations. If the study does not specifically indicate the relationship between mutations and their correspondence treatment, the main treatment studied in the article is marked.
  • Location: The source of the research data.
Literature Information
  • Sequence Data: The study provides the data accession number.